Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Houssein A Sater"'
Autor:
Elizabeth Lamping, Christian S Hinrichs, Edward McClay, Lisa M Cordes, Andrew Hill, Byoung Chul Cho, Sébastien Salas, Laureen S Ojalvo, P Alexander Rolfe, Margaret E Gatti-Mays, Jason M Redman, Houssein A Sater, Andrea Burmeister, Genevieve Jehl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor (TGF)-βRII (a TGF-β ‘trap’) fused to a human IgG1 mAb blocking programmed cell death ligand 1. This is
Externí odkaz:
https://doaj.org/article/8d0952dbd2c84693b0a6b1394990bc11
Autor:
Arun Rajan, Renee N Donahue, Jeffrey Schlom, James L Gulley, Elizabeth Lamping, Osama Rahma, Houssein Abdul Sater, Jennifer L Marté, Beatriz Walter-Rodriguez, Yulia Vugmeyster, Yo-Ting Tsai, Shania Bailey, Wiem Lassoued, Richy Agajanian, Andrew Weisman, Rena Ito, Masashi Sato, Andreas Machl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Bintrafusp alfa, a first-in-class bifunctional fusion protein targeting transforming growth factor-β (TGF-β) and programmed cell death ligand 1, has demonstrated encouraging efficacy as second-line treatment in patients with non-small ce
Externí odkaz:
https://doaj.org/article/299f4d847daa42ea885a8c75c936bce7
Autor:
James L Gulley, Ravi Madan, Jennifer Marte, Fatima Karzai, Amy Hankin, Houssein Abdul Sater, Manuk Manukyan, William Dahut, Shania Bailey, Wiem Lassoued, Michell Manu, Peter Pinto, Daniel Burnett, Kenneth Canubas, Nikki William
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d25a5872f13a4fdb8aacbef6001b8049
Autor:
James L Gulley, Jennifer Marte, Houssein Abdul Sater, Michael Xu, William Kelly, Wiem Lassoued, Kenneth Canubas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/51873a19c0b34aad86c8ef3470881f08
Autor:
Yvette Robbins, Sarah Greene, Jay Friedman, Paul E Clavijo, Carter Van Waes, Kellsye P Fabian, Michelle R Padget, Houssein Abdul Sater, John H Lee, Patrick Soon-Shiong, James Gulley, Jeffrey Schlom, James W Hodge, Clint T Allen
Publikováno v:
eLife, Vol 9 (2020)
Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. This approach may still be limited by the presence of immunosuppressive myeloid populations.
Externí odkaz:
https://doaj.org/article/c2df21fadf264488a0684e775401ddeb
Autor:
Anson T. Ku, Uma Shankavaram, Shana Y. Trostel, Hong Zhang, Houssein A. Sater, Stephanie A. Harmon, Nicole V. Carrabba, Yang Liu, Bradford J. Wood, Peter A. Pinto, Peter L. Choyke, Radka Stoyanova, Elai Davicioni, Alan Pollack, Baris Turkbey, Adam G. Sowalsky, Deborah E. Citrin
Publikováno v:
medRxiv
STRUCTURED ABSTRACTBackgroundPatients with localized prostate cancer have historically been assigned to clinical risk groups based on local disease extent, serum prostate specific antigen (PSA), and tumor grade. Clinical risk grouping is used to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0552ceab467acbc6433d0757a0544b43
https://doi.org/10.1101/2023.05.01.23288883
https://doi.org/10.1101/2023.05.01.23288883
Autor:
James W. Hodge, Jeffrey Schlom, Houssein Abdul Sater, Rika Fujii, Benjamin Wolfson, Kristen Solocinski, Michelle R. Padget, Anthony S. Malamas, Kellsye P. Fabian
Supplemental figures s1-s3 and supplementary table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8283f054f681cf562a94a185e717e50
https://doi.org/10.1158/2326-6066.22543390
https://doi.org/10.1158/2326-6066.22543390
Autor:
James W. Hodge, Jeffrey Schlom, Houssein Abdul Sater, Rika Fujii, Benjamin Wolfson, Kristen Solocinski, Michelle R. Padget, Anthony S. Malamas, Kellsye P. Fabian
Immunotherapy of immunologically cold solid tumors may require multiple agents to engage immune effector cells, expand effector populations and activities, and enable immune responses in the tumor microenvironment (TME). To target these distinct phen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f8c7c67f98dcbaf90b406c99ca1760
https://doi.org/10.1158/2326-6066.c.6550240
https://doi.org/10.1158/2326-6066.c.6550240
Autor:
Jason M Redman, Yo-Ting Tsai, Benjamin A Weinberg, Renee N Donahue, Shruti Gandhy, Margaret E Gatti-Mays, Houssein Abdul Sater, Marijo Bilusic, Lisa M Cordes, Seth M Steinberg, Jennifer L Marte, Caroline Jochems, Sunnie S Kim, John L Marshall, Sheri McMahon, Erica Redmond, Jeffrey Schlom, James L Gulley, Julius Strauss
Publikováno v:
Oncologist
Background FOLFOX plus bevacizumab is a standard of care (SOC) for first-line treatment of microsatellite-stable metastatic colorectal cancer (MSS mCRC). This study randomized patients to SOC or SOC plus avelumab (anti-PD-L1) plus CEA-targeted vaccin
Autor:
Margaret E Gatti-Mays, Nicholas P Tschernia, Julius Strauss, Ravi A Madan, Fatima H Karzai, Marijo Bilusic, Jason Redman, Houssein Abdul Sater, Charalampos S Floudas, Nicole J Toney, Renee N Donahue, Caroline Jochems, Jennifer L Marté, Deneise Francis, Sheri McMahon, Elizabeth Lamping, Lisa Cordes, Jeffrey Schlom, James L Gulley
Publikováno v:
Oncologist
Background NHS-IL12 is a first-in-class, recombinant fusion protein composed of the human monoclonal antibody NHS76 (binds exposed DNA/histones at sites of intratumoral necrosis) fused to 2 IL-12 heterodimers. The maximum tolerated dose (MTD) and rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a7630a6ed7d16e5f1ab6fdbfdf5cbb3
https://europepmc.org/articles/PMC10078919/
https://europepmc.org/articles/PMC10078919/